Investigational Drug Development
Looking Forward
Fujifilm is conducting research to study the potential of new drugs to address unmet medical needs, focusing on cancer, infectious diseases and central nervous system diseases.
Fujifilm currently has clinical trials in the United States for influenza, cancer, Alzheimer’s disease and COVID-19. These clinical trials are underway in collaboration with various institutions throughout the country.
In 2016, Fujifilm provided the anti-influenza drug favipiravir (T-705) to the Guinean Government, as one of the supplies procured by the Japanese government’s emergency grant aid to counter the outbreak of Ebola Virus disease.
*Avigan Tablet has not been approved by the FDA for use in the USA
Investigational drug pipeline
Infectious diseases
Code | Mode of Action | Indication | Region | Stage | Clinical Trial Information |
T-705 | RNA polymerase inhibitor | Influenza | Japan | Approved | https://clinicaltrials.gov/ct2/results?cond=&term=T-705&cntry=&state=&city=&dist= |
U.S.A. | Phase 3 | ||||
Severe fever with thrombocytopenia syndrome | Japan | Phase 3 | |||
Coronavirus disease 2019 (COVID-19) | Japan | IND filing | |||
U.S.A. | Phase 2 | ||||
T-3811 | Bacterial DNA gyrase inhibitor, topoisomerase V inhibitor |
Respiratory and urinary tract infection | China | IND filing | |
T-4288 | Bacterial protein synthesis inhibitor | Otorhinolaryngologic infections | Japan | IND filing | |
Respiratory tract infections | Japan | NDA filing |
Oncology
Code | Mode of Action | Indication | Region | Stage | Clinical Trial Information |
FF-10502-01 | DNA polymerase inhibitor | Advanced solid tumors | U.S.A. | Phase 2 | https://clinicaltrials.gov/ct2/results?cond=&term=FF-10502-01&cntry=&state=&city=&dist= |
FF-21101 | Anti P-cadherin antibody, 90Y conjugate |
Advanced solid tumors | Japan | Phase 1 | https://clinicaltrials.gov/ct2/results?cond=&term=FF-21101&cntry=&state=&city=&dist= |
U.S.A.1 | Phase 2 | ||||
FF-1311 | PSMA-targeted imaging agent, 99mTc labeled | Prostate cancer | Japan | Phase 2 | |
F-1515 | Somatostatin receptor targeted agent, 177Lu labeled | Neuroendocrine tumors | Japan | IND filing | |
F-1614 | Adrenergic neuron-blocking agent, 131I labeled |
Pheochromocytoma and paraganglioma | Japan | IND filing | |
FF-10101-01 | FLT3 inhibitor | Acute myeloid leukemia | U.S.A. | Phase 1 | https://clinicaltrials.gov/ct2/results?cond=&term=FF-10101-01&cntry=&state=&city=&dist= |
FF-10832 | Liposomal gemcitabine (DNA replication polymerase inhibitor) |
Advanced solid tumors | U.S.A. | Phase 1 | https://clinicaltrials.gov/ct2/results?cond=&term=FF-10832&cntry=&state=&city=&dist= |
FF-10850 | Liposomal topotecan (topoisomerase I inhibitor) |
Advanced solid tumors | U.S.A. | Phase 1 | https://clinicaltrials.gov/ct2/results?cond=&term=FF-10850&cntry=&state=&city=&dist= |
1 Phase 1 expansion study
Neurology
Code | Mode of Action | Indication | Region | Stage | Clinical Trial Information |
T-817MA | Neuroprotectant, microglial modulator, neuroplasticity facilitator | Alzheimer’s disease | Japan | Phase 2 | https://clinicaltrials.gov/ct2/results?cond=&term=T-817MA&cntry=&state=&city=&dist= |
Others
Code | Mode of Action | Indication | Region | Stage | Clinical Trial Information |
FF-10501-01 | IMPDH inhibitor | Myelodysplastic syndromes | Japan | Phase 1 | https://clinicaltrials.gov/ct2/results?cond=&term=FF-10501-01&cntry=&state=&city=&dist= |
Expanded access/Compassionate use
Currently, FUJIFILM Pharmaceuticals U.S.A., Inc. is not accepting expanded access/compassionate use requests.
Partnership Strategy
We are seeking the following partners:
- Companies interested in clinical development and commercialization of Fujifilm’s pipeline drugs.
- Companies willing to provide immune checkpoint inhibitors for, and/or co-sponsor clinical development of, combination therapies with Fujifilm liposomal drugs (FF-10832 and FF-10850).